Treatment effect modifiers Vitreoretinal interface status may significantly modify the response to therapy with anti-VEGF agents. Hyaloidal separation appears to facilitate penetration of drug, so that fewer injections need to be administered, however, visual acuity is not affected. Eyes with epiretinal membrane may require more injections due to anatomic disturbance, reduced penetration, or associated inflammation.